Key result
Targeted vaccination with Rotarix was the only efficient strategy from a societal perspective (ICUR €23,638/QALY), whereas universal vaccination would require price drops of 36.9% to 44.6% to become efficient.
Why the study?
Is universal rotavirus vaccination cost-effective compared to targeted or no vaccination in Spain?
Is universal rotavirus vaccination cost-effective compared to targeted or no vaccination in Spain?
Universal rotavirus vaccination in Spain is not currently cost-effective at a €25,000/QALY threshold unless vaccine prices drop significantly.
Answers are grounded in this paper and cite their sources.
Targeted Rotarix vaccination may be efficient at current prices; leaves open universal adoption without major price reductions or confirmatory trials.
Background Two vaccines against rotavirus diseases, Rotarix® and RotaTeq®, are being marketed in Spain; but rotavirus is not among diseases covered by universal vaccination in Spain. The aim was to assess the efficiency of extending Spain’s current targeted rotavirus vaccination strategy including only preterm babies, to a policy of universal vaccination. Methods A de novo cohort-based Markov model was built to evaluate the efficiency of three rotavirus vaccination strategies in Spain, i.e., targeted, universal, and no vaccination. Using Rotarix® or RotaTeq®, we compared the cost-utility of these strategies from both a societal and Spanish National Health System (SNHS) perspective. The model represents the most important clinical events conceivably linked to rotavirus infection. Efficacy, effectiveness, safety, costs and utilities were identified by systematic reviews. Results Incremental cost-utility threshold (ICUR) is €23,638/QALY (Quality Adjusted Life Year) for targeted vaccination with Rotarix®. The ICUR for the rest of the strategies evaluated are above €30,000/QALY. Sensitivity analysis shows the price as the only parameter that could make the universal vaccination strategy efficient. Conclusions Considering a threshold of €25,000/QALY, only targeted vaccination with Rotarix® from the societal perspective would be efficient. Price drops of 36.9% for Rotarix® and 44.6% for RotaTeq® would make universal vaccination efficient.
No takes yet. Share an insight, caveat, or question.
Imaz-Iglesia et al. (2023) studied Rotavirus infection (n=400,000). Rotavirus vaccination (Rotarix or RotaTeq) vs. No vaccination or targeted vaccination was evaluated on Incremental cost-utility ratio (ICUR) from a societal perspective (ICUR €23,638/QALY). Targeted vaccination with Rotarix was the only efficient strategy from a societal perspective (ICUR €23,638/QALY), whereas universal vaccination would require price drops of 36.9% to 44.6% to become efficient.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: